Tetraphase Pharmaceuticals, Inc. (TTPH)

[rusty8350]

$220 million in cash / 51 million outstanding shares

=

$4.31 per share, in CASH $$$


With multiple phase 3 trials already completed and a near guarantee that EU and FDA will approve Eravacycline for cIAI and have multiple other trials ongoing that can lead to other clinical indications which would add to this value.

Eracacycline alone could have sales of $100's of millions a year, justifying a market cap of many magnitudes higher than where this is currently trading.